Neumora Therapeutics, Inc. Common Stock (NMRA)
Neumora Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for central nervous system (CNS) disorders. It leverages innovative neuroscience science and digital health tools to create precision medicines aimed at improving outcomes for patients with neurological and psychiatric conditions.
Company News
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, highlighting its pipeline of novel neurological treatments, including a potential NLRP3 inhibitor for obesity and a vasopressin receptor antagonist for Alzheimer's disease agitation.
Neumora Therapeutics, Inc. is being investigated for potential securities fraud violations after its experimental depression treatment failed the first of three planned studies, causing an 81.42% drop in its stock price.
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
The IPO market is poised for what look like some decent-sized deals from profitable companies.